BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 32338768)

  • 21. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
    Willems-Jones A; Kavanagh L; Clouston D; Bolton D; ; Fox S; Thorne H
    BJU Int; 2012 Dec; 110(11 Pt C):E1181-6. PubMed ID: 23035815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Germline copy number variation analysis in Finnish families with hereditary prostate cancer.
    Laitinen VH; Akinrinade O; Rantapero T; Tammela TL; Wahlfors T; Schleutker J
    Prostate; 2016 Feb; 76(3):316-24. PubMed ID: 26552734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer.
    Lee DJ; Hausler R; Le AN; Kelly G; Powers J; Ding J; Feld E; Desai H; Morrison C; Doucette A; Gabriel P; Genetics Center R; Judy RL; Weaver J; Kember R; Damrauer SM; Rader DJ; Domchek SM; Narayan V; Schwartz LE; Maxwell KN
    Eur Urol; 2022 Jun; 81(6):559-567. PubMed ID: 34711450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial Findings from a High Genetic Risk Prostate Cancer Clinic.
    Sessine MS; Das S; Park B; Salami SS; Kaffenberger SD; Kasputis A; Solorzano M; Luke M; Vince RA; Kaye DR; Borza T; Stoffel EM; Cobain E; Merajver SD; Jacobs MF; Milliron KJ; Caba L; van Neste L; Mondul AM; Morgan TM
    Urology; 2021 Oct; 156():96-103. PubMed ID: 34280438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.
    Kote-Jarai Z; Leongamornlert D; Saunders E; Tymrakiewicz M; Castro E; Mahmud N; Guy M; Edwards S; O'Brien L; Sawyer E; Hall A; Wilkinson R; Dadaev T; Goh C; Easton D; ; Goldgar D; Eeles R
    Br J Cancer; 2011 Oct; 105(8):1230-4. PubMed ID: 21952622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.
    Edwards SM; Evans DG; Hope Q; Norman AR; Barbachano Y; Bullock S; Kote-Jarai Z; Meitz J; Falconer A; Osin P; Fisher C; Guy M; Jhavar SG; Hall AL; O'Brien LT; Gehr-Swain BN; Wilkinson RA; Forrest MS; Dearnaley DP; Ardern-Jones AT; Page EC; Easton DF; Eeles RA;
    Br J Cancer; 2010 Sep; 103(6):918-24. PubMed ID: 20736950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
    Giri VN; Hegarty SE; Hyatt C; O'Leary E; Garcia J; Knudsen KE; Kelly WK; Gomella LG
    Prostate; 2019 Mar; 79(4):333-339. PubMed ID: 30450585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing.
    Giri VN; Hartman R; Pritzlaff M; Horton C; Keith SW
    JCO Precis Oncol; 2022 May; 6(1):e2200234. PubMed ID: 35666082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers.
    Gleicher S; Kauffman EC; Kotula L; Bratslavsky G; Vourganti S
    Prostate; 2016 Sep; 76(13):1135-45. PubMed ID: 27225637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polygenic Risk Score Modifies Prostate Cancer Risk of Pathogenic Variants in Men of African Ancestry.
    Hughley RW; Matejcic M; Song Z; Sheng X; Wan P; Xia L; Hart SN; Hu C; Yadav S; Lubmawa A; Kiddu V; Asiimwe F; Amanya C; Mutema G; Job K; Ssebakumba MK; Ingles SA; Hamilton AS; Couch FJ; Watya S; Conti DV; Darst BF; Haiman CA
    Cancer Res Commun; 2023 Dec; 3(12):2544-2550. PubMed ID: 38014910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate Cancer Screening in a New Era of Genetics.
    Cheng HH; Pritchard CC; Montgomery B; Lin DW; Nelson PS
    Clin Genitourin Cancer; 2017 Dec; 15(6):625-628. PubMed ID: 28697982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease.
    Mijuskovic M; Saunders EJ; Leongamornlert DA; Wakerell S; Whitmore I; Dadaev T; Cieza-Borrella C; Govindasami K; Brook MN; Haiman CA; Conti DV; Eeles RA; Kote-Jarai Z
    Br J Cancer; 2018 Jul; 119(1):96-104. PubMed ID: 29915322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic landscape of homologous recombination repair genes in early-onset/familial prostate cancer patients.
    Paulo P; Cardoso M; Brandão A; Pinto P; Falconi A; Pinheiro M; Cerveira N; Silva R; Santos C; Pinto C; Peixoto A; Maia S; Teixeira MR
    Genes Chromosomes Cancer; 2023 Dec; 62(12):710-720. PubMed ID: 37436117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
    Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
    BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer.
    Gheybi K; Jiang J; Mutambirwa SBA; Soh PXY; Kote-Jarai Z; Jaratlerdsiri W; Eeles RA; Bornman MSR; Hayes VM
    J Natl Compr Canc Netw; 2023 Mar; 21(3):289-296.e3. PubMed ID: 36898365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications.
    Brandão A; Paulo P; Teixeira MR
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of Pathogenic Variants With Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients With Prostate Cancer and Melanoma.
    AlDubayan SH; Conway JR; Camp SY; Witkowski L; Kofman E; Reardon B; Han S; Moore N; Elmarakeby H; Salari K; Choudhry H; Al-Rubaish AM; Al-Sulaiman AA; Al-Ali AK; Taylor-Weiner A; Van Allen EM
    JAMA; 2020 Nov; 324(19):1957-1969. PubMed ID: 33201204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease.
    Sipeky C; Tammela TLJ; Auvinen A; Schleutker J
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1158-1166. PubMed ID: 34012061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
    Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.